Welcome to our dedicated page for Core Laboratories SEC filings (Ticker: CLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reservoir porosity tables, propellant acronyms, and global drilling statistics crowd Core Laboratories’ latest SEC reports. If you’re paging through a 300-plus page CLB annual report just to confirm how much revenue Production Enhancement contributed or when the next debt tranche matures, time is slipping away. Investors searching “Core Laboratories SEC filings explained simply” deserve a faster way to extract what matters.
Stock Titan applies natural-language AI to every new document the moment it hits EDGAR. Our platform:
- Delivers Core Laboratories annual report 10-K simplified with side-by-side plain-English summaries.
- Pulls key metrics from each Core Laboratories quarterly earnings report 10-Q filing and highlights segment trends.
- Sends real-time alerts for Core Laboratories Form 4 insider transactions real-time, so you never miss executive stock moves.
- Decodes Core Laboratories 8-K material events explained within minutes.
Need to track “Core Laboratories executive stock transactions Form 4” before a material event? Want a quick “Core Laboratories earnings report filing analysis” without reading footnotes? Our AI surfaces production-enhancement backlog data, international revenue share, ROIC targets, and capital-return commentary. You’ll also find “Core Laboratories proxy statement executive compensation” details, cash-flow sensitivity to oil prices, and “understanding Core Laboratories SEC documents with AI” case studies—all in one place. Every filing type, from Core Laboratories insider trading Form 4 transactions to shelf registrations, is updated continuously, giving professionals the clarity they need.
Core Laboratories Inc. (CLB): The Vanguard Group filed Amendment No. 3 to Schedule 13G, reporting beneficial ownership of 3,047,390 shares of common stock, representing 6.49% of the class as of 09/30/2025.
Vanguard reports 0 shares with sole voting power and 287,217 shares with shared voting power. It has 2,714,143 shares with sole dispositive power and 333,247 shares with shared dispositive power. Vanguard is identified as an investment adviser (IA), and states the securities were acquired and are held in the ordinary course of business. Vanguard’s clients have the right to receive dividends or sale proceeds related to these shares, and no single client’s interest exceeds 5%. The filing includes a certification that the holdings were not acquired to change or influence control of the issuer.
Core Laboratories (CLB) reported steady Q3 results. Revenue was $134.5 million, essentially flat year over year, while net income attributable to the company rose to $14.2 million, up 21%. Diluted EPS was $0.30 versus $0.25 a year ago. Services grew modestly to $101.1 million as international crude‑assay and diagnostics offset softer U.S. activity. Product sales declined to $33.4 million on weaker U.S. onshore completions.
Operating income improved to $20.9 million, aided by cost efficiencies and lower interest expense. Other income included a final insurance recovery gain of about $5.2 million related to the Aberdeen facility. Cash was $25.6 million; long‑term debt was $117.0 million gross. On July 22, the company entered a $150.0 million amended credit facility, with about $131.9 million of borrowing capacity available at quarter‑end. The board declared a $0.01 dividend on October 22, 2025. Year to date, CLB repurchased 831,478 shares for $9.8 million. After quarter‑end, CLB acquired Solintec in Brazil for an initial $2.3 million plus up to $3.7 million contingent, bolstering Reservoir Description.
Core Laboratories Inc. (CLB) reported that it issued a press release announcing its financial results for the third quarter of 2025. The company also declared a quarterly cash dividend of $0.01 per share, payable to shareholders of record on November 3, 2025 and payable on November 24, 2025.
The press release is furnished as Exhibit 99.1. The information is being furnished under Items 2.02 and 7.01 and is not deemed filed for liability purposes.
Mark D. Tattoli, Senior Vice President, General Counsel & Secretary of Core Laboratories Inc. (CLB), reported insider transactions dated 10/01/2025. The filing shows a sale of 276 shares of Common Stock at $12.58 and a simultaneous award/issuance of 700 restricted shares with a $0 reported price. After these reported transactions the filing lists 16,994.621 shares beneficially owned directly and 1,694.842 shares held indirectly in a 401(k) plan.
The restricted shares vest annually over six years on each anniversary of the grant date per the award agreement. Multiple restricted-share grants are aggregated in the disclosed restricted-share total. The report is signed and dated 10/02/2025.
Disciplined Growth Investors, Inc. reports beneficial ownership of 5,440,884 common shares of Core Laboratories Inc., representing 11.6% of the class. The filing shows sole voting power over 4,942,266 shares and sole dispositive power over 5,440,884 shares. The filer certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. No group affiliations, subsidiaries, or additional arrangements are reported.
Form 4 filed on 08/05/2025 discloses two insider transactions by Mark D. Tattoli, Senior VP, General Counsel & Secretary of Core Laboratories Inc. (CLB).
- Exercise of Restricted Shares (Code M): 250 common shares were acquired at $0 on 08/01/2025 as previously granted restricted stock vested. Beneficial ownership rose to 16,393.621 direct shares after the exercise.
- Tax Withholding (Code F): 99 shares were withheld at $10.53 per share to satisfy tax obligations related to the vesting event.
Net result is an increase of 151 direct shares. The filer also reports 20 shares held in a custodial account and 1,694.842 shares in the company 401(k) plan. Following the transactions, Tattoli continues to hold 2,150 unvested restricted shares with multi-year vesting schedules.
No open-market sales or purchases occurred; activity reflects routine vesting and associated tax withholding. Given the small size relative to CLB’s float and market capitalization, the filing is immaterial to the company’s valuation but provides insight into ongoing equity compensation for senior management.
FAQ
What is the current stock price of Core Laboratories (CLB)?
What is the market cap of Core Laboratories (CLB)?
